Review
Published · Updated · 1 min read
GLP-1 receptor agonists: discontinuation before conception and caution during breastfeeding
What it means for practice
According to the summary of ACOG recommendations, GLP-1 receptor agonists should be stopped before conception and avoided during pregnancy outside clinical trials. Breastfeeding requires individual assessment and careful monitoring.
Summary
What was covered
The available abstract of the Pharmastar article summarizes recommendations from the American College of Obstetricians and Gynecologists (ACOG) on glucagon-like peptide-1 (GLP-1) receptor agonist use during pregnancy and breastfeeding. It focuses on insufficient human safety data, potential metabolic and nutritional effects, and individualized care.
Reported recommendations
- Discontinue use before conception.
- Avoid use during pregnancy except in clinical trials.
- During breastfeeding, consider each case individually with careful monitoring.
Reasons for caution
The abstract describes limited transfer of these drugs across the placenta and into breast milk. However, it highlights potential indirect effects on maternal and infant nutrition: limited transfer alone does not remove the concerns described in the article. The abstract provides no quantitative estimates of transfer or risk.
The article also emphasizes lifestyle interventions, personalized care, and further research. The abstract does not specify discontinuation intervals before conception for individual drugs or monitoring parameters during breastfeeding.
Source
-
GLP-1 in gravidanza e allattamento, nuove raccomandazioni ACOG. pharmastar.it.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
